Titles: H.R.2430 — 115th Congress (2017-2018)All Information (Except Text)

Short Titles

Short Titles as Enacted

FDA Reauthorization Act of 2017

Short Titles as Enacted for portions of this bill
  • Biosimilar User Fee Amendments of 2017
  • Generic Drug User Fee Amendments of 2017
  • Medical Device User Fee Amendments of 2017
  • Prescription Drug User Fee Amendments of 2017

Short Titles - House of Representatives

Short Titles as Passed House

FDA Reauthorization Act of 2017

Short Titles as Passed House for portions of this bill
  • Biosimilar User Fee Amendments of 2017
  • Generic Drug User Fee Amendments of 2017
  • Medical Device User Fee Amendments of 2017
  • Prescription Drug User Fee Amendments of 2017

Short Titles as Introduced

FDA Reauthorization Act of 2017

Short Titles as Introduced for portions of this bill
  • Biosimilar User Fee Amendments of 2017
  • Generic Drug User Fee Amendments of 2017
  • Medical Device User Fee Amendments of 2017
  • Prescription Drug User Fee Amendments of 2017

Short Titles - Senate

Short Titles as Passed Senate

FDA Reauthorization Act of 2017

Short Titles as Passed Senate for portions of this bill
  • Biosimilar User Fee Amendments of 2017
  • Generic Drug User Fee Amendments of 2017
  • Medical Device User Fee Amendments of 2017
  • Prescription Drug User Fee Amendments of 2017

Official Titles

Official Titles - House of Representatives

Official Title as Introduced

To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.